PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930097
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930097
The global normal saline for parenteral use market is witnessing steady growth, driven by the increasing demand for intravenous fluids in hospitals for conditions such as dehydration, electrolyte imbalance, sepsis, hemorrhage, and wound dressing. According to Fortune Business Insights, the market was valued at USD 3.91 billion in 2025 and is projected to grow to USD 4.17 billion in 2026, ultimately reaching USD 7.15 billion by 2034, reflecting a CAGR of 6.97% during 2026-2034. North America dominated the market in 2025 with a 39.46% share, largely due to the high uptake of 0.9% sodium chloride solutions and strategic investments by key players to expand production capacity.
Normal saline (0.9% sodium chloride) is one of the most commonly used crystalloid fluids, particularly recommended by the Surviving Sepsis Campaign (SSC) for fluid resuscitation in septic shock. The rising incidence of neonatal sepsis globally-diagnosed in 1 to 50 per 1,000 live births annually-further boosts demand for normal saline. Increasing hospital admissions, geriatric populations, and government guidelines recommending saline in critical care are additional growth drivers.
COVID-19 Impact
The COVID-19 pandemic had a temporary negative impact on market growth due to postponed elective surgeries and reduced hospital admissions. Over 28 million elective surgeries were canceled globally during the peak disruption, and organizations like ICU Med reported a 10.3% revenue decrease for IV solutions in the first half of 2020. Despite this setback, post-pandemic recovery and an increased focus on healthcare infrastructure have allowed the market to resume its growth trajectory.
Market Trends
Demand for normal saline spikes during flu seasons, particularly with severe strains such as H3N2. For example, the European Union reported up to 50 million influenza infections annually, driving hospitalizations and saline use. Similarly, the U.S. experienced 490,561 hospital admissions during the 2018-2019 flu season. These trends highlight the critical role of normal saline in patient hydration and medication delivery.
Market Growth Factors
Restraining Factors
The market faces challenges due to the shift toward balanced IV fluids. Studies indicate that balanced solutions reduce mortality and kidney damage compared to normal saline, influencing hospital adoption. For example, a Vanderbilt University study found one fewer death or severe kidney complication per 100 patients administered balanced fluids.
Market Segmentation
By Type:
By Application:
By Region:
Key Players
Major companies shaping the market include Baxter (U.S.), Kelun Group (China), B. Braun Melsungen AG (Germany), Fresenius Kabi AG (Germany), ICU Medical (U.S.), among others. These firms focus on R&D, strategic collaborations, and production capacity expansion. For example, in August 2022, Assure Infusions announced a fully automated IV fluids plant in Florida to meet high U.S. demand.
Conclusion
The global normal saline for parenteral use market is set for consistent growth, expanding from USD 3.91 billion in 2025 to USD 7.15 billion by 2034, driven by increasing hospitalizations, surgical procedures, sepsis incidence, and supportive government guidelines. Despite challenges from the shift to balanced fluids, innovations in packaging, distribution, and production capacity, along with rising demand across North America, Europe, and Asia Pacific, are expected to sustain market growth and ensure the widespread availability of saline for critical care applications globally.
Segmentation By Type
By Application
By Geography